A time-resolved fluorescence assay to identify small-molecule inhibitors of HIV-1 fusion

Journal of Biomolecular Screening

Volumn 12, Issue 6, 2007, Pages 865-874

  Dams, Géry ^a   Van Acker, Koen ^a   Gustin, Emmanuel ^a   Vereycken, Inge ^a   Bunkens, Lieve ^a   Holemans, Pascale ^a   Smeulders, Liesbet ^a   Clayton, Reginald ^a   Ohagen, Asa ^a   Hertogs, Kurt ^a  

^a TIBOTEC BVBA   (Belgium)

Author keywords

F rster resonance energy transfer; Fusion inhibitor; gp41; HIV 1; Screening

Indexed keywords

ALLOPHYCOCYANIN; ANTIVIRUS AGENT; EUROPIUM; LANTHANIDE; PEPTIDE; VIRUS GLYCOPROTEIN;

AMINO TERMINAL SEQUENCE; ARTICLE; CARBOXY TERMINAL SEQUENCE; CELL MEMBRANE; FLUORESCENCE ANALYSIS; FLUORESCENCE RESONANCE ENERGY TRANSFER; HIGH THROUGHPUT SCREENING; HOST CELL; HUMAN IMMUNODEFICIENCY VIRUS 1; HYDROPHOBICITY; MEMBRANE FUSION; PRIORITY JOURNAL; PROTEIN INTERACTION; VALIDATION PROCESS;

AMINO ACID SEQUENCE; ANTIVIRAL AGENTS; BINDING, COMPETITIVE; FLUORESCENCE RESONANCE ENERGY TRANSFER; HIV ENVELOPE PROTEIN GP41; HIV-1; MICROBIAL SENSITIVITY TESTS; MODELS, MOLECULAR; MOLECULAR SEQUENCE DATA; PEPTIDE FRAGMENTS; SEQUENCE HOMOLOGY, AMINO ACID; VIRUS INTERNALIZATION;

HUMAN IMMUNODEFICIENCY VIRUS 1;

EID: 34548348136     PISSN: 10870571     EISSN: 1552454X     Source Type: Journal    
DOI: 10.1177/1087057107304645     Document Type: Article

References (26)

1. Gallo SA, Finnegan CM, Viard M., Raviv Y., Dimitrov A., Rawat SS,, et al. The HIV Env-mediated fusion reaction. Biochim Biophys Acta 2003 ; 1614: 36-50.
2. Eckert DM, Kim PS: Mechanisms of viral membrane fusion and its inhibition. Annu Rev Biochem 2001 ; 70: 777-810.
3. Wild CT, Shugars DC, Greenwell TK, McDanal CB, Matthews TJ: Peptides corresponding to a predictive alpha-helical domain of human immunodeficiency virus type 1 gp41 are potent inhibitors of virus infection. Proc Natl Acad Sci USA 1994 ; 91: 9770-9774.
4. Kilby JM, Hopkins S., Venetta TM, DiMassimo B., Cloud GA, Lee JY,, et al. Potent suppression of HIV-1 replication in humans by T-20, a peptide inhibitor of gp41-mediated virus entry. Nat Med 1998 ; 4: 1302-1307.
5. Chan DC, Fass D., Berger JM, Kim PS: Core structure of gp41 from the HIV envelope glycoprotein. Cell 1997 ; 89: 263-273.
6. Chan DC, Chutkowski CT, Kim PS: Evidence that a prominent cavity in the coiled coil of HIV type 1 gp41 is an attractive drug target. Proc Natl Acad Sci USA 1998 ; 95: 15613-15617.
7. Lu M., Blacklow SC, Kim PS: A trimeric structural domain of the HIV-1 transmembrane glycoprotein. Nat Struct Biol 1995 ; 2: 1075-1082.
8. Root MJ, Steger HK: HIV-1 gp41 as a target for viral entry inhibition. Curr Pharm Des 2004 ; 10: 1805-1825.
9. Liu S., Jiang S.: High throughput screening and characterization of HIV-1 entry inhibitors targeting gp41: theories and techniques. Curr Pharm Des 2004 ; 10: 1827-1843.
10. Ryu J-R., Lee J., Choo S., Yoon SH, Woo E-R., Yu YG: Development of an in vitro assay system for screening of gp41 inhibitory compounds. Mol Cells 1998 ; 8: 717-723.
11. Jin B-S., Lee W-K., Ahn K., Lee MK, Yu YG: High-throughput screening method of inhibitors that block the interaction between 2 helical regions of HIV-1 gp41. J Biomol Screen 2005 ; 10: 13-19.
12. Mo H., Konstantinidis AK, Stewart KD, Dekhtyar T., Ng T., Swift K.,, et al. Conserved residues in the coiled-coil pocket of human immunodeficiency virus type 1 gp41 are essential for viral replication and interhelical interaction. Virology 2004 ; 329: 319-327.
13. Frey G., Rits-Volloch S., Zhang X-Q., Schooley RT, Chen B., Harrison SC: Small molecules that bind the inner core of gp41 and inhibit HIV envelope-mediated fusion. Proc Natl Acad Sci USA 2006 ; 103: 13938-13943.
14. Gochin M., Savage R., Hinckley S., Cai L.: A fluorescence assay for rapid detection of ligand binding affinity to HIV-1 gp41. Biol Chem 2006 ; 387: 477-483.
15. Hemmilä I., Webb S.: Time-resolved fluorometry: an overview of the labels and core technologies for drug screening applications. Drug Discov Today 1997 ; 2: 373-381.
16. Selvin PR: Principles and biophysical applications of lanthanide-based probes. Annu Rev Biophys Biomol Struct 2002 ; 31: 275-302.
17. Eckert DM, Malashkevich VN, Kim PS: Crystal structure of GCN4-pIQI, a trimeric coiled coil with buried polar residues. J Mol Biol 1998 ; 284: 859-865.
18. Lu M., Kim PS: A trimeric structural subdomain of the HIV-1 transmembrane glycoprotein. J Biomol Struct Dyn 1997 ; 15: 465-471.
19. Mathis G.: Rare earth cryptates and homogeneous fluoroimmunoassays with human sera. Clin Chem 1993 ; 39: 1953 -1959.
20. Lambert DM, Zhou J., Medinas R.: HIV-1 isolates from patients treated with T-20 are sensitive to the second generation fusion inhibitor T-1249. Paper presented at the Third International Workshop on Drug Resistance and Treatment Strategies, San Diego, June 23-26, 1999.
21. Greenberg ML, Davison D., Jin L., Mosier S., Melby T., Sista P.,, et al. In vitro antiviral activity of T-1249 a second generation fusion inhibitor. Antivir Ther 2002 ; 7: S10.
22. Liu S., Lu H., Niu J., Xu Y., Wu S., Jiang S.: Different from the HIV fusion inhibitor C34, the anti-HIV drug Fuzeon (T-20) inhibits HIV-1 entry by targeting multiple sites in gp41 and gp120. J Biol Chem 2005 ; 280: 11259-11273.
23. Wang S., York J., Shu W., Stoller MO, Nunberg JH, Lu M.: Interhelical interactions in the gp41 core: implications for activation of HIV-1 membrane fusion. Biochemistry 2002 ; 41: 7283-7292.
24. De Clercq E.: Emerging anti-HIV drugs. Expert Opin Emerg Drugs 2005 ; 10: 241-274.
25. Zhao X., Singh M., Malashkevich VN, Kim PS: Structural characterization of the human respiratory syncytial virus fusion protein core. Proc Natl Acad Sci USA 2000 ; 97: 14172-14177.
26. Inglese J., Auld DS, Jadhav A., Johnson RL, Simeonov A., Yasgar A.,, et al. Quantitative high-throughput screening: a titration-based approach that efficiently identifies biological activities in large chemical libraries. Proc Natl Acad Sci USA 2006 ; 103: 11473-11478.